Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.

Related Articles


Evaluation of β-blocker Dose Optimisation Among Patients Attending Heart…

Yii Ching Wong, Tiong Kiam Ong, Yee Ling Cham,


Citation: European Cardiology Review 2021;16:e71.

The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction…

Yoichi Sunagawa, Ayumi Katayama, Masafumi Funamoto,


Citation: European Cardiology Review 2021;16:e68.

Early Initiation of Tolvaptan is Associated with Early Discharge in…

Shunsuke Kiuchi, Shinji Hisatake, Yoshiki Murakami,


Citation: European Cardiology Review 2021;16:e67.

Discovery of Novel Small Molecules for Heart Failure Therapy Using…

Satoshi Shimizu, Miho Yamada, Takahiro Katagiri,


Citation: European Cardiology Review 2021;16:e66.